

Appl. No. 10/608,886  
Amendment and Response to Restriction Requirement  
Page 14 of 16

### REMARKS

The present invention relates to compositions and methods for treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer. More particularly, the present invention relates to the use of proteins, peptides and biomolecules that bind to PAR-2 and inhibit the processes associated with the activation of that receptor.

The Office Action mailed May 31, 2006 recites that Claims 1-20 were canceled and Claims 21-37 are pending in this application. Applicants respectfully submit that Claims 1-20 are pending in the above-identified application. A continuation application was filed on April 27, 2004 (Serial No. 10/833,252), in which a Preliminary Amendment was filed canceling Claims 1-20 and adding new Claims 21-40. It is respectfully submitted that the Preliminary Amendment filed April 27, 2004, has been misfiled in the instant application and that document should be expunged from the file history. A telephone call to the Examiner was made regarding the error in the claims pending in the instant application. The Examiner requested that the undersigned agent proceed to respond to the Office Action mailed May 31, 2006, in order to correct the record to show that Claims 1-20 are the claims under consideration in this application.

Several paragraphs of the specification, as well as the claims and abstract, have been amended to correct typographical errors. Pursuant to 37 C.F.R. § 1.121(f), no new matter has been added in the amendments. Support for the amendment of the term "protein activated receptor" to "proteinase activated receptor" may be found at page 11, line 7, of the specification. Further, it is well established in the scientific community that PAR is an acronym for "proteinase activated receptor".

In response to the Office Action dated May 31 2006, Claims 1-7 are pending. Claims 1-6 are amended herein. Claims 8-20 are withdrawn. The withdrawn method claims have been amended to depend from composition Claim 1. No new matter has been added. Applicants submit the following remarks in an effort to address the rejections raised in the Office Action.

Appl. No. 10/608,886  
Amendment and Response to Restriction Requirement  
Page 15 of 16

### ***Restriction Requirement***

In the Office Action dated May 31, 2006, the Examiner requested restriction to one of the following inventions as required under 35 U.S.C. 121:

- Group I. Claims 21-30 and 38-40 drawn to a plurality of peptides, proteins, and biomolecules, classified in class 530, subclass 330.
- Group II. Claims 31-37, drawn to a method of treatment, classified in class 530, subclass 333.

The Examiner stated that the inventions of Group I and II are related as between product and process claims. Further, the Examiner stated that the inventions of Group I and II are patentably distinct from each other and have acquired separate status in the art, requiring independent searches. Applicants respectfully traverse the Examiner's restriction requirement. Inasmuch as the claims pending in this application are Claims 1-20, and in view of the amendments submitted herewith, applicants respectfully request withdrawal of the restriction requirement. Applicants submit that, as amended, the method claims of Group II include the composition of Group I, and therefore, any search of Group I should necessarily encompass Group II.

In order to facilitate prosecution, applicants herein elect the composition claims (Claims 1-7) and have withdrawn the method claims (Claims 8-20). Further, applicants have amended the method claims for purposes of rejoinder. Applicants understand that in the event a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP 821.04.

Applicants further reserve the right to file divisional applications on the remaining subject matter contained in the claims of Groups I and II at a later time.

### ***Species Election***

In the Office Action mailed May 31, 2006, the Examiner further required an election of species under 35 U.S.C. 121. Applicants respectfully traverse the Examiner's species requirement. All of the species listed in the claims relate to proteinase activated receptor antagonists and as such are all obvious variants thereof. However, in order to facilitate

Appl. No. 10/608,886  
Amendment and Response to Restriction Requirement  
Page 16 of 16


prosecution, applicants elect SEQ ID NO:1. The claims readable thereon include amended Claims 3 and 5, as well as withdrawn Claims 10, 12, 16, and 18.

### CONCLUSION

Applicants respectfully submit that Claims 1-7 (as well as withdrawn Claims 8-20) are fully enabled, novel and non-obvious over the cited art. Applicants assert that the claims are in condition for allowance and respectfully request that the method claims are rejoined and the application passed to issuance.

If the Examiner believes that any informalities remain in the case, which may be corrected by Examiner's amendment, or that there are any other issues which can be resolved by a telephone interview, a telephone call to the undersigned agent at (404) 745-2502 is respectfully solicited.

Respectfully submitted,



Shirley E. Brosmore  
Reg. No. 56,167

KILPATRICK STOCKTON LLP  
1100 Peachtree Street, Suite 2800  
Atlanta, Georgia 30309-4530  
(404) 815-6500  
Our Docket: 05213-3041 (43170-286877)